SARS-CoV-2 infection: efficacy of extensive vaccination of the healthcare workforce in a large Italian hospital.
Journal
La Medicina del lavoro
ISSN: 0025-7818
Titre abrégé: Med Lav
Pays: Italy
ID NLM: 0401176
Informations de publication
Date de publication:
23 Dec 2021
23 Dec 2021
Historique:
received:
06
08
2021
accepted:
08
11
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
A prospective observational study involved 13,787 Health Care Workers (HCWs) of a large hospital to assess the effectiveness of a SARS-CoV-2 mRNA vaccine. The daily incidence of infections was estimated from 1st October 2020 to 30th April 2021 and compared with that of the province of Turin (2.26 million). In the middle of this period, a mass vaccination began among HCW, and its effect was assessed. In the first half-period, 1,163 positive HCWs were observed, the average daily incidence rate per 100,000 being 79.58 (± 15.58; 95% CI) compared to 38.54 (± 5.96; 95% CI) in the general population (p<0.001). The vaccination campaign immunized 9,843 HCWs; among them, the average daily incidence was 14.23 (± 2.73; 95% CI) compared to 34.2 (± 2.95; 95% CI) in the province (p<0.001). Among fully vaccinated HCW, 59 cases were observed, giving rise to an incidence of 6.3 (± 2.66; 95% CI) much lower than in the province (p<0.001). In the second half of the observation period, the RR for HCWs compared to the province dropped from 2.07 (1.96 - 2.18; 95% CI; p<0.001) to 0.5 (0.42 - 0.58; 95% CI; p<0.001) and to 0.17 (0.13 - 0.22; 95% CI; p<0.001) for unvaccinated and vaccinated HCWs, respectively. The RR of vaccinate HCW was 0.43 (0.31 - 0.58; 95% CI; p<0.001) compared to unvaccinated. In the second half of the observation period, unvaccinated HCWs had a RR of 0.21 (0.18 - 0.25; 95% CI; p<0.001) as compared to the first one. A linear regression model (R2 = 0.87) showed that every percent increase in vaccinated HCWs lowered daily incidence by 0.94 (0.86 - 1.02; IC 95%; p<0.001). Vaccinated HCWs had a RR of 0.09 (0.07 - 0.12; 95% CI; p<0.001) compared to unvaccinated HCWs, which led to estimated effectiveness of the two-dose vaccine of 91 % (± 3 %; CI 95%) similar to that reported by the manufacturer.
Sections du résumé
BACKGROUND
BACKGROUND
A prospective observational study involved 13,787 Health Care Workers (HCWs) of a large hospital to assess the effectiveness of a SARS-CoV-2 mRNA vaccine.
METHODS
METHODS
The daily incidence of infections was estimated from 1st October 2020 to 30th April 2021 and compared with that of the province of Turin (2.26 million). In the middle of this period, a mass vaccination began among HCW, and its effect was assessed.
RESULTS
RESULTS
In the first half-period, 1,163 positive HCWs were observed, the average daily incidence rate per 100,000 being 79.58 (± 15.58; 95% CI) compared to 38.54 (± 5.96; 95% CI) in the general population (p<0.001). The vaccination campaign immunized 9,843 HCWs; among them, the average daily incidence was 14.23 (± 2.73; 95% CI) compared to 34.2 (± 2.95; 95% CI) in the province (p<0.001). Among fully vaccinated HCW, 59 cases were observed, giving rise to an incidence of 6.3 (± 2.66; 95% CI) much lower than in the province (p<0.001). In the second half of the observation period, the RR for HCWs compared to the province dropped from 2.07 (1.96 - 2.18; 95% CI; p<0.001) to 0.5 (0.42 - 0.58; 95% CI; p<0.001) and to 0.17 (0.13 - 0.22; 95% CI; p<0.001) for unvaccinated and vaccinated HCWs, respectively. The RR of vaccinate HCW was 0.43 (0.31 - 0.58; 95% CI; p<0.001) compared to unvaccinated. In the second half of the observation period, unvaccinated HCWs had a RR of 0.21 (0.18 - 0.25; 95% CI; p<0.001) as compared to the first one. A linear regression model (R2 = 0.87) showed that every percent increase in vaccinated HCWs lowered daily incidence by 0.94 (0.86 - 1.02; IC 95%; p<0.001). Vaccinated HCWs had a RR of 0.09 (0.07 - 0.12; 95% CI; p<0.001) compared to unvaccinated HCWs, which led to estimated effectiveness of the two-dose vaccine of 91 % (± 3 %; CI 95%) similar to that reported by the manufacturer.
Identifiants
pubmed: 34939622
doi: 10.23749/mdl.v112i6.12124
pmc: PMC8759049
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines, Synthetic
0
mRNA Vaccines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-476Références
Drugs. 2021 Mar;81(4):495-501
pubmed: 33683637
Mol Ther. 2008 Nov;16(11):1833-40
pubmed: 18797453
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Clin Infect Dis. 2020 Nov 19;71(16):2218-2221
pubmed: 32179890
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Euro Surveill. 2021 Apr;26(17):
pubmed: 33928898
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Vaccines (Basel). 2021 Apr 01;9(4):
pubmed: 33915829
Med Lav. 2021 Dec 23;112(6):444-452
pubmed: 34939621
J Control Release. 2015 Nov 10;217:345-51
pubmed: 26264835
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Jul 8;385(2):e8
pubmed: 33979507
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
J Infect Dis. 2022 Jan 5;225(1):30-33
pubmed: 34726239
BMJ. 2020 Oct 28;371:m3582
pubmed: 33115726
N Engl J Med. 2021 May 6;384(18):1774-1775
pubmed: 33755376
Emerg Infect Dis. 2021 Apr;27(4):1220-1222
pubmed: 33522478
Lancet. 2020 Nov 28;396(10264):1732-1733
pubmed: 33125934
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Vaccines (Basel). 2020 Aug 25;8(3):
pubmed: 32854391
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279